05545569 is referenced by 50 patents and cites 99 patents.

TGF-beta activators and TGF-beta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis following angioplasty, vascular bypass grafts, transplanted organs, atherosclerosis or hypertension are characterized by a reduced vessel lumen diameter. In a preferred embodiment of the invention, TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose are also amenable to chronic use for prophylactic purposes with respect to disease states involving proliferation and/or migration of vascular smooth muscle cells over time. Further provided is a method for determining TGF-beta in vitro, thereby identifying a patient at risk for atherosclerosis and monitoring a recipient that has received one or more administrations of a TGF-beta activator or production stimulator.

Title
Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
Application Number
61714
Publication Number
5545569
Application Date
May 25, 1995
Publication Date
August 13, 1996
Inventor
Peter L Weissberg
Cambridge
GB
James C Metcalfe
Cambridge
GB
David J Grainger
Cambridge
GB
Agent
Schwegman Lundberg Woessner & Kluth P A
Assignee
NeoRx Corporation
WA, US
IPC
G01N 33/543
View Original Source